ASSESSMENT OF THE PROGNOSTIC POTENTIAL OF EXPRESSION AND ABERRATIONS IN THE NUMBER OF DNA COPIES OF THE HOMOLOGICAL RECOMBINATION SYSTEM GENES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
M. Tsyganov, E.O. Rodionov, M. Ibragimova, S. S. Sorokovikova, A. A. Karchevskaya
{"title":"ASSESSMENT OF THE PROGNOSTIC POTENTIAL OF EXPRESSION AND ABERRATIONS IN THE NUMBER OF DNA COPIES OF THE HOMOLOGICAL RECOMBINATION SYSTEM GENES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER","authors":"M. Tsyganov, E.O. Rodionov, M. Ibragimova, S. S. Sorokovikova, A. A. Karchevskaya","doi":"10.18137/cardiometry.2023.29.conf.25","DOIUrl":null,"url":null,"abstract":"Numerous studies have shown that the presence of homologous recombination deficiency (HRD) in breast tumors may be a good marker of the effectiveness of chemotherapy with DNA-damaging agents such as platinum-based and anthracycline-containing medication regimens. However, the formation of HRD due to disruptions in the BRCA1/2 genes is typical not only for breast cancer and ovarian cancer, but also for other cancer localizations, in particular for non-small cell lung cancer (NSCLC). Since the use of platinum-based drugs in patients with NSCLC is a standard treatment protocol, studying the expression profile of homologous recombination genes and the presence of chromosomal aberrations therein will allow us to fully study HRD in these patients and identify new prognostic markers.","PeriodicalId":41726,"journal":{"name":"Cardiometry","volume":"69 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiometry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18137/cardiometry.2023.29.conf.25","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Numerous studies have shown that the presence of homologous recombination deficiency (HRD) in breast tumors may be a good marker of the effectiveness of chemotherapy with DNA-damaging agents such as platinum-based and anthracycline-containing medication regimens. However, the formation of HRD due to disruptions in the BRCA1/2 genes is typical not only for breast cancer and ovarian cancer, but also for other cancer localizations, in particular for non-small cell lung cancer (NSCLC). Since the use of platinum-based drugs in patients with NSCLC is a standard treatment protocol, studying the expression profile of homologous recombination genes and the presence of chromosomal aberrations therein will allow us to fully study HRD in these patients and identify new prognostic markers.
期刊介绍:
Cardiometry is an open access biannual electronic journal founded in 2012. It refers to medicine, particularly to cardiology, as well as oncocardiology and allied science of biophysics and medical equipment engineering. We publish mainly high quality original articles, reports, case reports, reviews and lectures in the field of the theory of cardiovascular system functioning, principles of cardiometry, its diagnostic methods, cardiovascular system therapy from the aspect of cardiometry, system and particular approaches to maintaining health, engineering peculiarities in cardiometry developing. The interdisciplinary areas of the journal are: hemodynamics, biophysics, biochemistry, metrology. The target audience of our Journal covers healthcare providers including cardiologists and general practitioners, bioengineers, biophysics, medical equipment, especially cardiology diagnostics device, developers, educators, nurses, healthcare decision-makers, people with cardiovascular diseases, cardiology and engineering universities and schools, state and private clinics. Cardiometry is aimed to provide a wide forum for exchange of information and public discussion on above scientific issues for the mentioned experts.